Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This is a report on a 15 year old patient with malignant teratoma grade III of the right ovary in stage Ia (FIGO). The adequate treatment of this rare tumors which occurs preponderant in children and adolescents supposes an accurate and thorough histologic analysis. Our patient was treated initially by unilateral oophorectomy followed by an polychemotherapy with Vincristine, Actinomycin D and Cyclophosphamide. Regular monitoring of the tumor markers AFP and beta-HCG before and after surgery is indispensable to control the development.
 ...
PMID:[Malignant teratoma of the ovary in childhood and adolescence--a case report]. 164 63

It has been reported that hepatoma (HCC) cells produce abnormal proteins such as erytropietin, fibrinogen, prothrombin, and, recently, antithrombin III (AT III). In a preliminary report, we reported increased AT III levels in patients bearing HCC independent of their clinical liver status. The present study was performed to assess antithrombin III levels and other serological data present in patients with cirrhosis and in patients with cirrhosis and clinical findings of neoplastic disease. In 70 well-matched patients (47 with cirrhosis and 23 with cirrhosis and proven HCC) serum total cholesterol, albumin, prothrombin, alkaline phosphatase, AFP, aminotransferases, and AT III were determined. Together with AFP and alkaline phosphatase, patients with HCC had higher values of AT III (88 +/- 7%) and total cholesterol (184 +/- 17 mg/100 ml), as compared with cirrhotic patients (AT III 56 +/- 3.6%; total cholesterol 113 +/- 5 mg/100 ml) (P less than 0.001). No difference was observed between these two groups for albumin, prothrombin, and aminotransferases. In HCC patients, AT III levels were related to the total cholesterol level (R2 = 0.317), whereas in the cirrhotic patients it correlated with the prothrombin level (R2 = 0.274). These data suggest that in HCC patients a greater rate of synthesis of AT III occurs, whereas in cirrhotic patients lower levels of AT III occur due to impaired synthesis or increased catabolism of the protein. The serial determination of AT III in cirrhotic patients as a means of detecting neoplastic transformation is suggested.
 ...
PMID:Hepatocarcinoma in cirrhosis. Is antithrombin III a neoplastic marker? 164 42

The inaccessibility of radiolabeled antibody to poorly vascularized regions of solid tumors may reduce the therapeutic efficacy of these macromolecules. Theoretical mathematical models have predicted that increasing the protein dose administered would reduce the heterogeneity of radioantibody distribution. This investigation was undertaken to evaluate this hypothesis in experimental animal models. We have utilized the technique of macroautoradiography to demonstrate an increase in tumor penetration of the lower-affinity 125I-labeled NP-4 or higher-affinity Immu-14 anti-carcinoembryonic antigen (anti-CEA) mAbs into small (60.25-0.4 g) and large (0.8-1.5 g) GW-39 and LS174T human colonic xenografts, grown subcutaneously in the nude mouse, when 400 micrograms unlabeled antibody is administered simultaneously with 10 micrograms (100 microCi) radioantibody. Further increases in protein to 800 micrograms result in a reduction in total tumor uptake of the antibody. These in a reduction in total tumor uptake of the antibody. These differences in mAb distribution could be visualized as early as 1 day after antibody injection. Improved mAb penetration was also achieved for the Mu-9 anti-CSAp (anti-mucin) antibody using 800 micrograms unlabeled antibody. An irrelevant antibody (AFP-7-31) was found to be homogeneously distributed 3 days after injection, even at a low protein dose. Attempts to improve mAb penetration by increasing the protein dose in the GS-2 colorectal tumor, a model that has low NP-4 accretion as a result physiological barriers separating antibody from antigen, were not successful. These results suggest that a more homogeneous distribution of radioantibody can be achieved by carefully selecting a dose of unlabeled antibody to coadminister. Work is currently in progress to determine the effect of improved tumor distribution of radioantibody on the therapeutic potential of a single dose of radioantibody.
 ...
PMID:The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. 165 55

99mTc-PMT delayed hepatobiliary imaging was performed preoperatively in 62 patients with small hepatocellular carcinoma. All patients received operation and had pathological proof. All these tumors were smaller than 5 cm in size. Liver scan was done 5 min, 2 and 5 hr after administration of radiopharmaceutics. The sensitivity was 33.3% (2/6), 41.2% (7/17), 60.0% (9/15) and 54.2% (13/24) in tumors with sizes of less than or equal to 2 cm, 2-3 cm, 3-4 cm and 4-5 cm groups, respectively. The positive rates in the first two groups were lower than in the last two groups but much higher than those by conventional imaging. The total positive rate was 50.0%. The difference was not significant in comparison with the group of tumor size greater than 5 cm. The smallest mass detectable was only 1.2 cm in diameter. The uptake of radiopharmaceutic was not related to serum AFP level and hepatic cirrhosis (P greater than 0.05). These results show that 99mTc-PMT delayed hepatobiliary imaging may be useful in the diagnosis, particularly in the pathognomonic diagnosis, of small hepatocellular carcinoma.
 ...
PMID:[Diagnostic value of 99mTc-PMT delayed hepatobiliary imaging in small hepatocellular carcinoma--an analysis of 62 cases]. 165 87

Sixty patients with primary hepatic carcinoma (PHC) were treated with transcatheter hepatic artery infusion chemotherapy (TAI) and embolization (TAE) from June 1988 to December 1989. There were 54 males and 6 females. Their age ranged from 22 to 72 years with an average of 52. Course of disease ranged from 1/2 to 12 months. In these 60 cases, 31 had Stage II and 29 Stage III lesions. Using Seldinger's method per femoral artery, conventional hepatic angiography was performed. Afterwards, adriamycin or cisplatin infusion was carried out, followed by chemoembolization therapy of tumor vessels using mixture of ethiodized oil or iophendylate and mitomycin C. Finally, gelatin sponge block was used for proximal arterial embolization. After the treatment procedure, abdominal pain was relieved, tumor reduced in size, AFP, r-GT, AKP and LDH declined to various degrees and the survival time was prolonged. The 3-, 6- and 12-month survival rates were 93.3% (56/60), 67.3% (37/49) and 33.3% (9/27), respectively. It is indicated that TAI and TAE, being safe and effective, is the treatment of choice for patients with unresectable PHC.
 ...
PMID:[Transcatheter hepatic artery infusion chemotherapy and embolization for 60 patients with primary hepatic carcinoma]. 165 88

The majority of patients have 'good risk' nonseminomatous germ cell tumors, that is, they are likely to obtain an initial complete response to chemotherapy. Trials in these patients attempt to reduce the toxicity of chemotherapy. The minority of patients have refractory disease ('poor risk' nonseminomatous germ cell tumors) and the primary objective in this population is to improve the proportion of complete response. Chemotherapy trials for the poor risk group are generally associated with greater toxicity. Clinical factors reported to impact on the prognosis of nonseminomatous germ cell tumor patients include the pretreatment level of serum tumor markers (AFP, HCG, LDH), extern or bulk of disease, the pathology and the site of the primary lesion. No consensus currently exists on which factors are most important in determining prognosis and how they should be used to allocate patients to good and poor risk nonseminomatous germ cell tumors trials. The data support the concept that biologic markers and extent or bulk of disease together are more predictive of response and survival than either one alone and their combined use results in a smaller percent of the germ cell tumor population allocated to poor risk trials. This minimizes exposure of good risk patients to toxic regimens and still maintains a high response rate in the good risk population. The current eligibility criteria for good and poor risk trials in use directly affects the reported response proportion and survival. In view of these differences, good and poor risk trials should be randomized against a comparative control population and nonrandomized trials comparing treatment results with those of other studies or historical controls should be viewed with extreme caution.
 ...
PMID:Assessment of risk in metastatic testis carcinoma: impact on treatment. 165 78

A case of Prader-Willi syndrome who later developed hepatoblastoma is reported. Prader-Willi syndrome was suspected because of hypotonia, hypopigmentation, and undescended testes when he was a newborn infant. The diagnosis was confirmed by chromosome analysis, which showed 46XY del(15)(q11, q13). When he was 1 year 4 months old, a liver tumor and high serum AFP were found. At operation a large tumor arising from the caudate lobe was found and the tumor was totally resected. After completion of the hepatectomy, he developed circulatory collapse of unknown cause and died shortly after the operation. Histopathologic examination revealed that the tumor was composed of two components, well differentiated cells and poorly differentiated cells. The well differentiated part did not dominate the poorly differentiated part, so it was diagnosed as poorly differentiated hepatoblastoma. This is the first reported case of Prader-Willi syndrome with a pediatric malignant tumor.
 ...
PMID:Prader-Willi syndrome with del(15)(q11,q13) associated with hepatoblastoma. 166 44

A new human cholangiocarcinoma cell line (HuCCA-1) was established from cholangiocarcinoma (CCA) tissue fragments surgically removed from a Thai patient with intrahepatic bile duct cancer. The growth medium used for the primary cell culture was Ham's F12 supplemented with 10% fetal bovine serum (FBS) and 10 ng/ml epithelial growth factor (EGF). Approximately one month later, the cells were subcultured in Ham's F12 supplemented with only 10% FBS. The population doubling time was approximately 55 hr. Staining of the cells for cytokeratin and mucin confirmed that the cells were mucin-secreting tumor of epithelial cell origin. The supernatant fluid secreted a number of non-specific tumor markers including CA125 and traces of MCA and AFP. The ability of the HuCCA-1 cell line to synthesize specific marker that may have potential in the diagnosis of cholangiocarcinoma is now being investigated.
 ...
PMID:Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. 166 51

The expression of the embryonal and of the differentiational proteins in 12 cases of chordoma and in the notochord of a 4-month-old and a 5-month-old human embryo have been examined immunohistologically by the ABC method using polyclonal antibodies to CEA, AFP, or S-100, and the monoclonal antibody to cytokeratin. It was found that S-100 was expressed in all cases of chordoma and in the notochords examined. CEA and cytokeratin also were found expressed in some cases of chordoma but not in the notochords. These proteins were found expressed more strongly in chordomas without a metastasis than in those with a metastasis. In the metastatic lesions, these proteins were expressed more strongly than in the primary lesions. The antibody to AFP reacted with neither the chordomas nor the notochords tested. These results suggest a possible link between the gene-expression of the tumor cells and the microenvironment in which they are harbored.
 ...
PMID:[Expression of embryonal and differentiational proteins in chordomas and in the notochord]. 168 59

A 49-year-old male patient was admitted to our hospital complaining of right scrotal mass. Serum tumor markers, HCG, beta-HCG and AFP, were all elevated. After right high inguinal orchiectomy, a pathological report revealed a mixed-type germ cell tumor, which was composed of choriocarcinoma, embryonal carcinoma and seminoma. Because of persistent elevation of these tumor markers, RPLND was performed. There were viable tumor cells in the dissected lymph node specimens. As pulmonary metastases developed after RPLND, the patient was treated with 3 courses of VAB-6 combination chemotherapy (vinblastine, actinomycin-D, cyclophosphamide, bleomycin and cis-platinum). Pulmonary metastases disappeared and tumor markers returned to normal range except for moderate elevation of serum HCG. Two months later, pulmonary metastases developed again with re-elevation of tumor markers. Four courses of EP salvage chemotherapy (etoposide and cisplatinum) were given. After EP chemotherapy, the patient was given etoposide orally for about 7 months. During this period, no abnormality was found except for slight elevation of serum HCG. Five months after discontinuing chemotherapy, serum HCG returned to normal and complete remission was obtained.
 ...
PMID:[A case of complete remission obtained with etoposide cis-platinum combination chemotherapy in advanced testicular cancer]. 168 34


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>